Michael Torres focuses on innovation at the intersection of technology, medicine, and healthcare delivery. His coverage spans medical devices, digital health, diagnostics, and emerging care models. At The Catalyst Brief, Michael evaluates how new tools translate from concept to real-world impact, considering clinical evidence, adoption challenges, and broader industry implications.
129 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Regulatory & PolicyBiogen and Eisai's application for a subcutaneous induction formulation of their Alzheimer’s disease therapy Leqembi has encountered a three-month review delay from the FDA. This extension allows additional time for reviewers to evaluate a significant amendment to the application, postponing the target action date to late August 2026.
Michael TorresMay 8, 2026
Biopharmaceutical IndustryAngelini Pharma has executed a transformative acquisition, purchasing Catalyst Pharmaceuticals to bolster its position in the rare disease therapeutic market. This acquisition aligns with Angelini's broader focus on neurological medicines and rare conditions, underpinned by Catalyst's FDA-approved drug Firdapse.
Michael TorresMay 8, 2026
Regulatory & PolicyRecently, a cruise ship experienced an outbreak attributed to hantavirus, resulting in fatalities and illnesses. This article explores the biology of hantavirus, symptoms, transmission, and how public health entities manage such outbreaks while maintaining public reassurance.
Michael TorresMay 5, 2026
Regulatory & PolicyThe issue of 'skinny labeling'—where generic drug manufacturers label their products to deliberately exclude patented uses—has emerged as a significant regulatory and legal challenge in the pharmaceutical industry. The Supreme Court’s recent deliberations could shape the landscape of generic drug market entry and patent enforcement.
Michael TorresApr 29, 2026
Biopharmaceutical IndustryThe pharmaceutical giant Pfizer has secured a legal settlement that delays generic competition for one of its top-selling drugs until 2031. This move has important implications for the pharmaceutical industry, generic manufacturers, and patients worldwide. The settlement highlights ongoing tensions between innovator companies and generic drugmakers, regulatory landscapes influencing market dynamics, and the strategic measures companies take to protect valuable assets.
Michael TorresApr 29, 2026
Regulatory & PolicyRecent allegations by the FDA focus on potentially manipulated data underpinning the approval of a leading autoimmune therapy developed by Amgen. This post analyzes the claims, the context of approval pathways, and the potential repercussions for the pharmaceutical industry and patients alike.
Michael TorresApr 29, 2026
Biopharmaceutical IndustryAfter partnering in early 2021 to develop RIPK1 blockers, Eli Lilly has disengaged from its alliance with Rigel Pharmaceuticals. This move follows Lilly's earlier withdrawal from one CNS-targeted program, highlighting the complexities and hurdles faced in advancing RIPK1 inhibitors. This post explores the implications of this development for the RIPK1 field and the broader pharmaceutical landscape.
Michael TorresApr 22, 2026
Biotech InnovationAt the American Association of Cancer Researchers' 2026 annual meeting, significant new data was unveiled showcasing the effectiveness of Revolution Medicines’ KRAS-targeting drug. This breakthrough treatment shows potential to redefine therapeutic strategies for cancers driven by KRAS mutations, a historically challenging target in oncology.
Michael TorresApr 20, 2026
Biopharmaceutical IndustryTrilliant Health's recent report reveals a dramatic 62% surge in behavioral health demand over the past several years. Despite this growth, systemic issues such as clinician shortages and accessibility challenges continue to impede care delivery, underscoring the complex landscape facing the behavioral health industry today.
Michael TorresApr 18, 2026
Biopharmaceutical IndustryIn recent transactions, leading biopharma companies such as Gilead, AstraZeneca, and Vertex have pursued acquisitions that emphasize the value of skilled staff and research teams. This trend marks a strategic focus on human capital as a key driver of innovation and competitive advantage in the sector.
Michael TorresApr 15, 2026
Medical TechnologyHealthcare IT is evolving rapidly with major health systems adopting innovative solutions to overcome the challenges of AI implementation stuck in pilots. This post explores the key reasons these top systems are investing in new health IT categories and what it means for the future of healthcare delivery and management.
Michael TorresApr 14, 2026
Biotech InnovationAntibody drug conjugates (ADCs) represent a promising class of targeted cancer treatments that deliver cytotoxic agents directly to tumors. Recent mega-round funding for biotech startups Sidewinder Therapeutics and Stipple Bio underscores the growing interest and innovation in this space. Both companies are on track to enter clinical trials next year to test their novel approaches aimed at overcoming limitations of current ADCs and refining their specificity and effectiveness.
Michael TorresApr 12, 2026